Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Failure ≥3 Lines of Therapies”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Early research (Phase 1)Looking for participantsNCT07748533
What this trial is testing

HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.

Who this might be right for
Autoimmune Hemolytic Anemia (AIHA)
Juventas Cell Therapy Ltd. 9
Testing effectiveness (Phase 2)Study completedNCT00316199
What this trial is testing

Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company 60
Early research (Phase 1)Active Not RecruitingNCT06231368
What this trial is testing

CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.

Who this might be right for
Autoimmune Hemolytic AnemiaAutologous CD19 CAR-TFailure of Three or More Lines of Therapy
Institute of Hematology & Blood Diseases Hospital, China 6
Large-scale testing (Phase 3)UnknownNCT04429152
What this trial is testing

ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance

Who this might be right for
HIV-1-infection
Professor Francois Venter 25
Early research (Phase 1)Not Yet RecruitingNCT06770504
What this trial is testing

YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia

Who this might be right for
Autoimmune Hemolytic AnemiaAnti-CD19 STAR T-cell TherapyFailure ≥3 Lines of Therapies
Institute of Hematology & Blood Diseases Hospital, China 7
Large-scale testing (Phase 3)Active Not RecruitingNCT06935409
What this trial is testing

Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure

Who this might be right for
Osteosarcoma
Hansoh BioMedical R&D Company 117
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07817654
What this trial is testing

Trastuzumab Combined With Retlirafusp Alfa in Treating HER2（Human Epidermal Growth Factor Receptor 2） 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-line Systemic Therapy Failure

Who this might be right for
GCGEJC
Henan Cancer Hospital 35
Large-scale testing (Phase 3)Study completedNCT03150875
What this trial is testing

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd. 290
Large-scale testing (Phase 3)Study completedNCT00928187
What this trial is testing

Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)

Who this might be right for
HIVHIV Infections
ANRS, Emerging Infectious Diseases 454
Large-scale testing (Phase 3)Ended earlyNCT00676650
What this trial is testing

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Who this might be right for
Prostatic Neoplasms
Pfizer 873
Early research (Phase 1)WithdrawnNCT02722135
What this trial is testing

Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed

Who this might be right for
Leukemia, Myeloid, Acute
Boehringer Ingelheim